Top Things to Know: Current Patterns and Best Practices for Prescribing Novel Heart Failure Medications in Children

Updated: November 19, 2026

  1. Pediatric heart failure (HF) arises from structural or functional cardiac disorders that impair ventricular filling and/or ejection. It is a complex condition with heterogeneous presentations driven by diverse etiologies and is associated with substantial morbidity, mortality, and health care burden.
  2. Guideline-directed medical therapy (GDMT), including angiotensin receptor–neprilysin inhibitors (ARNIs), sodium–glucose cotransporter 2 inhibitors (SGLT2i), and intravenous iron, remain under-investigated in children and are inconsistently prescribed, often requiring clinicians to extrapolate from adult data or practice without formal guidance.
  3. This science advisory details results from a survey of pediatric HF clinicians in the United States and Canada, focusing on prescribing practices, side effects, dosing experience, and clinician perspectives on the use of ARNIs, SGLT2i, and iron replacement therapy in children.
  4. Survey responses indicate variable adoption of these therapies, with a subset of clinicians infrequently prescribing ARNIs, SGLT2i, and iron replacement therapy.
  5. Reported barriers include insurance and cost constraints, limited pediatric-specific efficacy data, and the absence of formal guidance. Clinicians also expressed differing views on the level of evidence required for use in children, highlighting ongoing uncertainty regarding pharmacokinetic, safety, and efficacy data.
  6. Adoption of ARNIs (sacubitril/valsartan) in pediatric HF with reduced ejection fraction (HFrEF) is variable, often as a substitute for traditional renin–angiotensin system therapies (ACEi or ARBs). Tolerability concerns, particularly hypotension and dizziness, frequently prompt dose adjustment or discontinuation, and insurance denials for ARNIs and SGLT2i remain common.
  7. The benefit of routine transition from angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) to ARNIs in children is uncertain but may be considered in pediatric HFrEF based on clinical judgment, shared decision-making, and factors such as persistent symptoms, tolerability, and cost.
  8. Despite limited pediatric data, SGLT2i are used across the pediatric HF spectrum, including in single-ventricle and Fontan physiology, with potential benefit in select patients with preserved systolic function and signs of congestion.
  9. SGLT2i are not routinely prescribed by most pediatric HF clinicians. Use remains limited, with concerns centered on adverse effects such as urinary tract infections, acute kidney injury, and dehydration, alongside frequent insurance-related barriers.
  10. Iron deficiency is highly prevalent in pediatric HF and is associated with worse clinical outcomes, yet iron repletion remains underutilized, likely reflecting limited pediatric-specific evidence and variability in clinical practice.
  11. Overall, adoption of newer HF therapies in children remains inconsistent, shaped by gaps in pediatric evidence, variability in clinician perspectives, and practical barriers to implementation. Moving forward, innovative and feasible research approaches, such as registry-based randomized trials and adaptive platform designs, may help generate meaningful evidence to guide care and improve outcomes in this population.

Citation


Price JF, Hong B, Jacobson-Kelly AE, Jeewa A, Lin K, Martinez H, Menachem J, Procaccini D, Rossano J, Exil V; on behalf of the American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young, Pediatric Heart Failure and Transplantation Committee; Council on Clinical Cardiology; and Council on Cardiovascular and Stroke Nursing. Current patterns and best practices for prescribing novel heart failure medications in children: a science advisory from the American Heart Association. Circ Heart Fail. Published online November 19, 2026. doi: 10.1161/HHF.0000000000000092